Coptisine

Synonyms: 黄连碱; Coptisin
Coptisine 是一种存在于黄连中的具有口服活性且可穿透血脑屏障的生物碱,作为可逆性非竞争性 IDO 抑制剂(Ki 为 5.8 μM,IC50 为 6.3 μM),它可抑制神经炎症、减少 Aβ 斑块负荷并具有神经保护活性,通过阻断 NF-κB、MAPK 和 PI3K/Akt 的激活发挥抗炎活性,同时抑制癌细胞增殖并诱导 DNA 损伤、G2/M 期细胞周期阻滞、细胞凋亡 (apoptosis)、活性氧 (ROS) 产生及线粒体功能障碍;此外,Coptisine Sulfate 可在大鼠心肌缺血/再灌注模型中抑制 Rho/ROCK 通路激活,减少心律失常,限制心肌损伤标志物的释放,缩小梗死面积并保留心脏功能,而 Coptisine 还可下调 HMGCR、上调 LDLR 和 CYP7A1 以调控胆固醇代谢,降低血清血脂异常水平并促进粪便胆汁酸排泄,因此可用于癌症、高胆固醇血症、阿尔茨海默病、炎症性疾病和心血管疾病的研究。
产品编号: MS-Q92505 CAS No.: 3486-66-6 分子式: C19H14NO4 分子量: 320.32
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价

产品描述

Coptisine 是一种存在于黄连中的具有口服活性且可穿透血脑屏障的生物碱,作为可逆性非竞争性 IDO 抑制剂(Ki 为 5.8 μM,IC50 为 6.3 μM),它可抑制神经炎症、减少 Aβ 斑块负荷并具有神经保护活性,通过阻断 NF-κB、MAPK 和 PI3K/Akt 的激活发挥抗炎活性,同时抑制癌细胞增殖并诱导 DNA 损伤、G2/M 期细胞周期阻滞、细胞凋亡 (apoptosis)、活性氧 (ROS) 产生及线粒体功能障碍;此外,Coptisine Sulfate 可在大鼠心肌缺血/再灌注模型中抑制 Rho/ROCK 通路激活,减少心律失常,限制心肌损伤标志物的释放,缩小梗死面积并保留心脏功能,而 Coptisine 还可下调 HMGCR、上调 LDLR 和 CYP7A1 以调控胆固醇代谢,降低血清血脂异常水平并促进粪便胆汁酸排泄,因此可用于癌症、高胆固醇血症、阿尔茨海默病、炎症性疾病和心血管疾病的研究。

生物实验数据

生物活性 Coptisine is an orally active alkaloid found in Coptis chinensis that can cross the blood-brain barrier; as a reversible non-competitive IDO inhibitor with a Ki of 5.8 μM and an IC50 of 6.3 μM, it inhibits neuroinflammation, reduces Aβ plaque burden, and exhibits neuroprotective activity, exerts anti-inflammatory activity by blocking the activation of NF-κB, MAPK, and PI3K/Akt, and inhibits cancer cell proliferation while inducing DNA damage, G2/M cell cycle arrest, apoptosis, reactive oxygen species (ROS) production, and mitochondrial dysfunction; furthermore, Coptisine Sulfate inhibits Rho/ROCK pathway activation, reduces arrhythmias, limits the release of myocardial injury markers, reduces infarct size, and preserves cardiac function in a rat myocardial ischemia/reperfusion model, while Coptisine downregulates HMGCR and upregulates LDLR and CYP7A1 to regulate cholesterol metabolism, lower serum dyslipidemia levels, and promote fecal bile acid excretion, making it useful for research on cancer, hypercholesterolemia, Alzheimer's disease, inflammatory diseases, and cardiovascular diseases.
IC50 & Target IDO:6.3 μM.
体外研究
(In Vitro)

Coptisine (0.1-100 μM; 48 h) 可强效抑制人肺腺癌 A549、H460 和 H2170 细胞 (IC50 = 18.09、29.50 和 21.60 μM) 及其他受试人癌细胞系的增殖,对人正常脐静脉内皮细胞仅具有中等选择性。
Coptisine (12.5-50 μM; 48 h) 可在人肺腺癌 A549 细胞中诱导浓度依赖性 DNA 损伤,这一点可通过 γH2AX 表达水平的升高得到证实。
Coptisine (12.5-50 μM; 48 h) 可在人肺腺癌 A549 细胞中诱导浓度依赖性 G2/M 期细胞周期阻滞,其作用机制为下调 cyclin B1、cdc2 和 cdc25C 的表达并上调 p21 的表达。
Coptisine (12.5-50 μM; 48 h) 可在人肺腺癌 A549 细胞中诱导浓度依赖性凋亡,并诱导 caspase 3/7、caspase 8、caspase 9 呈浓度依赖性激活,促使 PARP 裂解,表明内源性和外源性凋亡通路均被激活。
Coptisine (12.5-50 μM; 0.5-24 h) 可在人肺腺癌 A549 细胞中诱导呈时间和浓度依赖性的活性氧生成。
Coptisine (12.5-50 μM; 24 h) 可在人肺腺癌 A549 细胞中诱导浓度依赖性线粒体功能障碍,包括线粒体膜电位丧失以及 Bax、Bcl-2 和细胞色素 c 的表达改变。
Coptisine 作为一种可逆的非竞争性抑制剂,可强效抑制重组人 IDO,其 Ki 为 5.8 μM,IC50 为 6.3 μM。
Coptisine 可抑制 HEK 293 细胞中的 IDO 活性,IC50 为 7.1 μM。
Coptisine (10 μM; 5 h 预处理) 可逆转 β-淀粉样蛋白 1-42 和干扰素-γ 诱导的 IDO 激活,并恢复 PC12 细胞的活力。
Coptisine 可通过阻断巨噬细胞中 NF-κB、MAPK、和 PI3K/Akt 的活化,抑制 LPS (MS-X54539) 诱导的炎症反应。

Western Blot Analysis

Cell Line: human lung adenocarcinoma A549
Concentration: 12.5, 25, 50 μM
Incubation Time: 48 h
Result: Caused a concentration-dependent upregulation of pH2AX, a marker of DNA double-strand breaks, relative to untreated control cells.

Cell Cycle Analysis

Cell Line: human lung adenocarcinoma A549
Concentration: 12.5, 25, 50 μM
Incubation Time: 48 h
Result: Caused concentration-dependent G2/M phase arrest, with 26.5%, 29.9%, and 36.8% of cells in G2/M phase after treatment with 12.5, 25, and 50 μM, respectively, compared to 16.95% in control cells.
Accompanied this arrest by concentration-dependent downregulation of cyclin B1, cdc2, and cdc25C, and upregulation of p21.

Apoptosis Analysis

Cell Line: human lung adenocarcinoma A549
Concentration: 12.5, 25, 50 μM
Incubation Time: 48 h
Result: Caused concentration-dependent induction of apoptosis: treatment with 50 μM resulted in 58.5% early apoptotic cells and 24.2% late apoptotic cells; treatment with 25 μM resulted in 26.4% early apoptotic cells; treatment with 12.5 μM resulted in 10.8% early apoptotic cells, compared to 8.6% early and 4.6% late apoptotic cells in control cultures.
Caused concentration-dependent activation of caspase 3/7, with a 19-fold increase in activity at 50 μM relative to control.
Induced concentration-dependent upregulation of active caspase 8, active caspase 9, and cleaved PARP.

Cell Viability Assay

Cell Line: PC12
Concentration: 10 μM (pre-incubation)
Incubation Time: 5 h (pre-incubation); 24 h (amyloid-β peptide 1-42 treatment); 24 h (interferon-γ treatment)
Result: Down-regulated the enhanced IDO activity induced by combined 25 μM amyloid-β peptide 1-42 and 1000 U/mL interferon-γ treatment.
Restored the reduced cell viability caused by these stimuli to levels comparable to untreated control cells.
体内研究
(In Vivo)

Coptisine (10-30 mg/kg;口服;缺血前 10 分钟单次给药,或在再灌注后 4 小时追加给药) 可通过减少心律失常、缩小心肌梗死面积、降低心肌酶释放、改善左心室功能障碍,同时抑制心肌细胞凋亡、炎症反应及 Rho/ROCK 通路激活,对大鼠心肌缺血/再灌注损伤发挥显著的心脏保护作用。
Coptisine (23.35-70.05 mg/kg/天;灌胃;每日给药;连续 4 周) 可剂量依赖性地改善高脂高胆固醇 (HFHC) 饲料喂养的叙利亚金黄仓鼠的高胆固醇血症。
Coptisine (482.5-1728 mg/kg;口服;单次给药) 对昆明小鼠的急性毒性较低,单次口服后的 LD50 为 880.18 mg/kg。
Coptisine (154 mg/kg/天;口服;每日;连续 90 天) 在 SD 大鼠中耐受性良好,连续 90 天每日口服给药未观察到毒性。
Coptisine (50 mg/kg;口服;每日 1 次,持续 1 个月) 可使 A-PPswe/PS1ΔE9 转基因阿尔茨海默病小鼠的血清 IDO 活性恢复正常,抑制神经炎症,减轻 Aβ 斑块负荷,恢复神经元完整性,并完全逆转认知障碍。
Coptisine 可通过叙利亚金黄地鼠体内的脂多糖/Toll 样受体 4 (LPS/TLR-4) 介导的信号通路,减轻肥胖相关炎症。

Animal Model: Sprague-Dawley (male, 280±20 g, left anterior descending coronary artery occlusion for 30 min followed by reperfusion)
Dosage: 3 mg/kg; 10 mg/kg; 30 mg/kg
Administration: p.o.; single dose 10 min before ischemia, plus an additional dose 4 h after reperfusion (24 h reperfusion studies); single dose 10 min before ischemia (3 h reperfusion studies)
Result: Significantly decreased I/R-induced arrhythmia score and reduced incidence of premature ventricular complexes and ventricular tachycardia.
Significantly reduced infarct size compared with I/R controls.
Significantly reduced serum levels of aspartate transaminase, lactate dehydrogenase, and creatine kinase-MB compared with I/R controls.
Significantly attenuated I/R-induced reductions in left ventricular ejection fraction and fractional shortening at 24 h post-reperfusion.
Significantly reduced the percentage of TUNEL-positive apoptotic cardiomyocytes, dose-dependently decreased cleaved caspase-3 expression, and upregulated Bcl-2 protein expression compared with I/R controls.
Reduced DNA fragmentation indicative of apoptosis.
Significantly decreased heart tissue levels of proinflammatory cytokines IL-1β, IL-6, and TNF-α, inhibited NF-κB p65 translocation from cytoplasm to nucleus, reduced Rho, ROCK1, and ROCK2 protein expression, and attenuated phosphorylation of myosin phosphatase targeting subunit-1 compared with I/R controls.
Animal Model: Syrian golden hamsters (male, 4-week-old, 100±5 g, HFHC diet-induced hypercholesterolemia)
Dosage: 23.35 mg/kg/day; 46.7 mg/kg/day; 70.05 mg/kg/day
Administration: I.g.; daily; 4 weeks
Result: Reduced serum total cholesterol (TC) by 10.9% and increased fecal cholesterol by 29% at 23.35 mg/kg.
Reduced serum TC by 24.3% and low-density lipoprotein cholesterol (LDL-c) by 20.0%, increased high-density lipoprotein cholesterol (HDL-c) by 24.8%, increased fecal cholesterol by 44% and fecal total bile acids (TBA) by 31.6% at 46.7 mg/kg.
Reduced serum TC by 26.7%, LDL-c by 22.2%, and triglycerides (TG) by 15.4%, increased HDL-c by 41.7%, increased fecal cholesterol by 51.5% and fecal TBA by 61.4% at 70.05 mg/kg.
Reduced body weight by 9.2% at 70.05 mg/kg/day after 33 days of treatment versus HFHC group.
Suppressed liver Hmgcr mRNA expression, increased liver Ldlr mRNA expression by 8.5-fold, 9.78-fold, and 11-fold, increased liver Cyp7a1 mRNA expression (21% increase at 70.05 mg/kg), and increased liver Srebp-2 mRNA expression across all doses versus HFHC group.
Reduced liver HMGCR protein expression by 16.4%, increased liver SREBP-2, LDLR, and CYP7A1 protein expression by 46.0%, 51.9%, and 107% at 70.05 mg/kg versus HFHC group.
Increased liver LDLR protein expression by 30.7% and CYP7A1 protein expression at 46.7 mg/kg versus HFHC group.
Animal Model: B6C3-Tg (APPswe, PSEN1dE9)85Dbo/J (A-PPswe/PS1ΔE9) (8-month-old male)
Dosage: 50 mg/kg
Administration: p.o.; once daily; 1 month
Result: Reduced escape latency to levels indistinguishable from wild-type mice.
Showed significantly shorter latency to first target crossing, increased number of target platform crossings, and increased time spent in the target quadrant, with performance matching wild-type mice.
Normalized serum IDO activity (measured by kynurenine/tryptophan ratio) to wild-type levels, without altering IDO mRNA or protein expression in brain tissue.
Reduced brain expression of GFAP (astrocytic activation marker) and CD11b (microglial activation marker) to wild-type levels.
Restored hippocampal MAP2 (neuronal marker) immunoreactivity in the CA1 region, which was reduced in AD control mice.
Significantly reduced hippocampal Aβ1-42 plaque burden to near wild-type levels.

化学信息

分子量 320.32
分子式 C19H14NO4
CAS No. 3486-66-6
别名 黄连碱; Coptisin

储存&溶解度

溶解度信息
DMSO: 3.91 mg/mL (12.21 mM), Sonication is recommended.
体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 0.39 mg/mL (1.22 mM), Suspension.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

黄连碱 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础